“Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 Resurface 1 And Resurface 2 Studies”. SKIN The Journal of Cutaneous Medicine, vol. 4, no. 5, Sept. 2020, p. s42, https://doi.org/10.25251/skin.4.supp.42.